Is Buying Altimmune Inc (NASDAQ:ALT) Here Good Idea?

October 2, 2018 - By Ellis Scott

The stock of Altimmune Inc (NASDAQ:ALT) registered an increase of 23.99% in short interest. ALT’s total short interest was 2.21 million shares in October as published by FINRA. Its up 23.99% from 1.78M shares, reported previously. With 540,300 shares average volume, it will take short sellers 4 days to cover their ALT’s short positions.

The stock increased 13.18% or $0.58 during the last trading session, reaching $4.98. About 2.84M shares traded or 1065.05% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 88.70% since October 2, 2017 and is downtrending. It has underperformed by 104.32% the S&P500.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $8.56 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

More notable recent Altimmune, Inc. (NASDAQ:ALT) news were published by: Seekingalpha.com which released: “Altimmune up 76% as rally continues” on September 20, 2018, also Benzinga.com with their article: “48 Biggest Movers From Yesterday” published on October 02, 2018, Nasdaq.com published: “Why Altimmune Stock Is Skyrocketing Today” on September 20, 2018. More interesting news about Altimmune, Inc. (NASDAQ:ALT) were released by: Seekingalpha.com and their article: “Altimmune jumps 99%” published on September 19, 2018 as well as Nasdaq.com‘s news article titled: “Altimmune Announces $4.9 million Registered Direct Offering of Common Stock” with publication date: September 24, 2018.

Altimmune, Inc. (NASDAQ:ALT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>